[Summary] 致力于引进海外肿瘤免疫治疗新药及先进的治疗技术
北京东方略生物医药科技有限公司致力于引进海外肿瘤免疫治疗新药及先进的治疗技术。东方略具备全球视野,关注癌症等未被满足的临床需求,聚焦海外临床研究阶段的创新药,在区域内进行临床开发、申请上市及商业化,实现中外新药同步上市。目前,东方略从两家纳斯达克上市公司Inovio Pharmaceuticals, Inc. 以及Tocagen Inc.分别获得高级别宫颈癌癌前病变治疗新药VGX-3100以及高级别神经胶质瘤治疗新药Toca 511&Toca FC在大中华地区的开发及商业化的权利。上述产品均处于国际III期临床阶段,产品上市后,有望填补国内空白,使广大患者获益。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows